CCO

engoac

CCO

jegerdog

Well CCO is but I admit the valuation looks a little frothy. The reason I mention Nuclear is because it is key to future power demand and is entirely missing in your thesis. Look at it this way, there are about 450 operational reactors globally with 120 now in formal planning and another 75 in active construction. Thats right now, I would expect the number of reactors in the pipeline to triple over the next 5 years. It depends on your timeline and whether you would look to stock pick or be comfortable taking a basket approach. But in any case, you are welcome - just an idea as you did ask.

BeautifulAuthor9167

Clustered insider selling is the ultimate tell. If the CCO is out, I’m looking for the exit too.

bobbybeansss

can i be CCO? Chief Cockerating Officer?

Extreme_Sort_3099

CCO is way less likely to fail- theyre already in the refining business. These other extraction names have way more potential upside but might also go belly up. The early extractor names are speculative plays imo, you might make a lot or you could lose it all, size positions accordingly.

SirLate6248

Leaps on NEE, CCO and FSLR. 🥭 delivered the best possible ad for clean energy. No more dino juice for anyone

useful_tool30

I hear they hired Salt Bae as CCO ( Chief Cooking Officer) to cook the books

TheTruthisStrange

3 months should be fairly good. Long term (years is iffy). But it is up about 280% over the last 5 years. What the next 5 years will hold is never guarateed. But their management is superb in that industry, and they are constantly growing organically, and through acquisition, and increase their dividend every year. An investor friend of mine has owned XOM and reinvesed dividends for 40-50 years and he's afraid to tell me how much he has made :):):):):). (My guess +$10-15M. Personally I don't own the stock itself, but I have Yieldmax Covered Call Options on the Stock (ticker: XOMO) which have done great this year. And the Fund Ticker is up \~14% itself YTD. Those CCO funds are not for eveyone so studying and picking the stablest funds is important, but I've studied and continue to study them closely on an ongoing basis and XOMO has been one of their best ones this year with the rise in oil prices. GDXY (a GDX CCO) ""was"" also great, but got hammered with the fall off in Gold over the last 2 weeks. It's recoved quite a bit today, but I'm not in it for now. If the middle east war finally calms down and Gold reverses up again that one will pay out nice weekly dividends. But having said all this, do your homework. Good luck now.

Alert-Ad5477

CCO may be punished for their throttling of U production

Thick-dk-boi

I’m sticking mostly with my Canadian stocks. Right now with TRI, CCO, and AII (already have 6x profit there).

nerf_squid

CCO! Might be a homer opinion working because I work in the sector but truly believe in the future of nuclear energy

Mottz86

Wrong. He worked for Abcellera and prior to that he was in Amgen. He worked for Lilly but not the CCO.

dragoon7201

don't feel bad brother. I held CCO for over 10 years bought in at 13 bucks a share. And sold at 60 last year, so there is that.

Moepenmoes

How high will uranium related stocks go? What's even driving them up? (UUUU, CCO, KAP etc.)

Classic_Profession87

CCO.

DopeBook

Hit those CCO and UUUU calls.

DopeBook

CCO.TO BHP GEV BWXT ATI (they supply turbine parts to GEV, Rolls Royce, and the other major players) And others

Lanky_Package_4302

Awesome man I’m going to buy some more CCO shares and get McDonald’s. Fml.

anemonaeae

Watching Immunome and Cameco. Was planning on buying CCO a couple of weeks ago but things got crazy around the holidays. This would be a long term hold

MF266

If I had to rank them purely on growth potential this year, I’d probably go GEV > BWXT > NBIS > CCO > APH. GEV and BWXT feel more catalyst-driven, while CCO and APH seem more tied to slower-moving macro trends.

No_Honeydew_2453

If I had to rank purely on growth potential (not safety) I'd go NBIS > BWXT > GEV > APH > CCO NBIS/BWXT feel like higher-beta growth plays, GEV solid but more priced in, APH steady compounder, CCO lowest growth.

KarinaNoir69

Funny how people can read the same documents but come to totally different conclusions. What I interpreted is that this confirms the CEO and the team are not mobile gaming people as they confirmed no desire to enter any regulated gaming markets (thus confirming why he backed out of WV making it very likely that they will have to pay out the 4.5 million dollar term fee plus legal costs. Also, if you look at Skillz they dominate the DFS space but still have the necessary regulatory structure in place so if VIPZ wants to be competitive to Skillz, which is less of a gaming company and more regulated payments + compliance moat type entity, VIPZ wouldn’t have given up the WV license. Which brings me to the fact that a gf of mine (who works in the industry) said that they heard from folks in TN that the compliance team left shortly after the new team came on board. She said they were very well respected so their departure speaks volumes of the current management/CEO and the likely deficiencies apparent in the CEO and the team which the opposite of what is needed in this very highly regulated space. Lastly, she says this space is likely to get regulated soon given the increased concern regarding responsible gaming (of any nature). If that does occur, to have a team without mobile gaming experience or even the desire to obtain/keep licenses is not a group I’d invest in as this is an inherently regulated space. Then add that the fact that the CFO, CCO and compliance team as a whole left right after the new CEO comes on board is either a coincidence or reflective of a much larger issue. I’m sure you’ll disagree but I had to put this out there so others don’t fall for this very biased hype of a very questionable penny stock. Happy investing to all.

Mr-Toyota

U/nickman23 Cameco's money makers are MacArthur, Cigar Lake. The latter being the richest uranium deposit in the world. The operations in Nebraska and Rabbit are just a side show. Hell they shutdown rabbit for a number of years to manage supply. CCO.TO is the Canadian ticker for those who are curious. And yes, I think CCO.TO has a lot of upward movement ahead of it. The joint venture with Brookfield to buy Westinghouse is looking better and better every day.

Mr__Accountant

URA, URNM, URNJ - all Uranium ETFs NXE, DNN, UUUU, CCO - great stocks to hold F3 Uranium, GLO - risky but attractive

DopeBook

CCO is usually a good bet depending on your timing. I’ve made money from calls and puts they have done well for me.

microwaffles

I bought some BEP and CCO is on my watchlist. With Cameco it's not what you're buying it's what your paying $$$

Yung_Ceejay

100% If you are buying options be prepared to exercise, if you are in shares hold until BO is announced and share price is close to BO value. The company doesn't have the staff to take the drugs to the market and is clearly positioned for M&A. They fired their sales team(CCO) and brought in Katherine Bach Kalin as an M&A expert. https://www.tipranks.com/news/the-fly/sellas-life-announces-departure-of-cco-francomano-general-counsel-wood

AntoniaFauci

Except CCO is the Canadian ticker, which is showing the amount that should be USD. It’s scrambled beyond recognition.

OtisB

Cameco is listed as CCO on mine

nerf_squid

CCO/CCJ (long term hold)

AntoniaFauci

Google finance is increasingly packed with errors. For instance, last two weeks, Cameco CCJ is missing. But then they weirdly started reporting it under the wrong ticker, the foreign one CCO.

Due-Papaya-6217

MIST wtf - only thing I can see is the CCO gifting shares to a family member Could be a short attack too - guess we’ll find out soon enough

Sensitive-Mango3216

This is solid advice, definitely escalate with FINRA if you haven't already. The demand letter to their CCO is smart too since compliance officers hate having regulatory heat on them One thing I'd add - document everything with timestamps and keep records of every single interaction you've had with RH support. If this goes to arbitration you're gonna want a paper trail showing their pattern of just ignoring you for 18+ months

Missjd87

This is solid advice. FINRA complaints actually get results because these companies \*have\* to respond - it's not like emailing customer support and getting ghosted by a bot. And honestly at this point OP has all the leverage: no charges, property returned, police clearance letters. Robinhood has zero legal standing to keep that account frozen, they're just being lazy or hoping OP gives up. The demand letter to the CCO is key too. Once compliance knows there's a paper trail going to regulators, suddenly things start moving real fast.

jubilantBeatbox

# Future Catalysts Several **near-term catalysts** could impact Biofrontera’s stock: 1. **FDA Approval for Expanded Ameluz Indications**: Potential approval for **moderate-to-severe acne vulgaris** (Phase 2b completed, last patient out in August 2025) \[Simply Wall St, Aug 26, 2025\]. 2. **Phase 3 Trial Results**: Data readout for **actinic keratosis on extremities, neck, and trunk** (patient enrollment completed March 2025) \[Simply Wall St, Mar 18, 2025\]. 3. **Superficial Basal Cell Carcinoma (sBCC) Study**: Achievement of key milestone in Phase 3 PDT trial \[Simply Wall St, Jan 8, 2025\]. 4. **Reimbursement Improvements**: Enhanced insurance coverage could boost adoption. 5. **Resolution of Nasdaq Listing Issues**: A reverse stock split or capital raise may be needed to regain compliance. 6. **Commercial Execution**: Success in scaling sales under new CCO George Jones. These catalysts could drive **revenue growth and margin expansion**, but execution risk remains high.

BunBun_75

Yes I had CCO at $27, sold half at 95, sold second half at $134 - then it hit 153…

DopeBook

Pump that CCO 🚀

LatentF

Personally; my side bets can be described as western rare magnets (Neo Performance Materials for example) & Heavy Rare Earth. Robotics will take off and currently they all need similar materials irrespective of which companies producing them win for lack of a better word. For example one area I'm currently looking into is potential western production of PEEK as a material which is produced primarily from DFNB which China controls nearly all of. Separately I like KAP and CCO for uranium and have various other side bets for lack of a better word: space, water treatment etc

chsws1

Edit: CEO and CCO bought shares today https://investor.sweetgreen.com/financials/sec-filings/default.aspx

JjJacob90

but the point is the pure exposure to the WEC upside is reduced. And that was reflected in the reaction in stock prices between CCO and BEP.

luv2block

Cameco is tied up with the AI boom. If AI stocks keep going up, CCO/CCJ does also. If the AI bubble pops, CCO will pop also. Perhaps not as much as core AI stocks and it will rebound faster, but it will crash initially (my guess is 50% range).

DarklingDarkwing

Nice to see CCO jump today. What else do you hold besides QNC in the quantum space?

jfwelll

Cant post good DD without a huge position, then ill do like bots and spam tickers BEP , BAM, CCO, TO THE MOOOOONNNN HAPPY NOW

Flaky_Team_3540

Everyone talking fake meat and openAI, and here I was sitting with 20k in $CCO, freat little canadian uranium company! :D

DeLordsCheeps

CCO/CCJ making a recovery

Radiant-Ad-9753

Uranium is not mentioned in any of their financial statements, my friend. "The CCO said" to who? A gas station attendant? This feels like a squeeze play on the back end of BYND.

LatentF

I prefer CCO and KAP, all in on the uranium:p

Canis9z

AI-Nuke bubble bust. Those startup SMR NNE, OKLO, SMR \~ -1/3 from highs The REAL nuke companies holding up better BWXT, GEV, CCO, CAT

WaveZealousideal2848

CCO you sob, help me with my losses lol

Klingervon

Clear Channel Outdoor. CCO

zbla_

Nuai squeeze And CCO moving good

WaveZealousideal2848

anyone know what's up with the CCO pop?

rotterdam-010

Well they had a revenue of 600.000 dollar and a loss of nearly 30 million, in Q2… according to investing.com the Ceo and CCO sold a part of their stocks. They really need a big breakthrough.

al323211

Explain? Their CEO and CCO hate making money.

JohnnyStrides

I have CCO and NXE in a 2:1 ratio. Thinking of ramping up NXE to match my Cameco holdings. The smartest thing to do would be just to grab one of the uranium ETFs probably (HURA in Canada). 

Gart19

I was buying CCO for $29 a share when I first entered the market in 2022. I wish I kept buying it monthly at DOC for the last 3 years.

SovietTankEnthusiast

Just asked the teacher, he doesn't want my portfolio to be too focused on one industry, and he wants me to focus more on the leadership vs actual gain. I have AAPL, NVDA, RHM, CCO, UBER, META, TSLA, JPM.

JohnnyStrides

Can also add in some MGA but I'm adding CCO/J & NXE at a 2:1 ratio and buying in weekly.

JohnnyStrides

CCO for some of us ;)

Inevitable_Low_7911

I just read CCO Severance Agreement. 

One-Title8698

Gold and Uranium are on the run. Still Time to be in now. UEC, UUUU, SCZ, GLCC, CCO, AYA

vendeep

Turned $250k CAD (March 2020) into ~$3.0M CAD by Aug 2025 (≈ $2.1M USD), a ~58% CAGR over ~5.4 years. Edge came from: timing (near the COVID bottom), concentrated conviction (mainly Cameco/CCO), very high savings rate (~90% of discretionary income), and staying invested.

NOLOVE90

NUKZ. It holds big names like CEG, GEV, and CCO but also companies in the nuclear field like OKLO and SMR that will help power the vision for AI into reality. Good entry price too.

RaidBoss3d

Yes, I actually heard about this stock from some DD done on Wall Street bets funny enough. I rand the DD through chat GPT and it looks and give feed back. Chat GPT said the following... This is one of the better Reddit DD write-ups I’ve seen in a long time — not perfect, but it lays out a compelling high-conviction, risk-reward thesis on $IOVA. Let me give you a full take: --- 🧠 TL;DR: Is this legit? Yes. If you're hunting a deep-value biotech rebound with massive short interest, real FDA-approved product, and asymmetric upside — this thesis is strong. It's not hype alone — it’s anchored in facts. --- 🔬 Let’s break it down: ✅ 1. Replimune’s failure is a huge tailwind Replimune ($REPL) getting a complete response letter from the FDA basically eliminates IOVA’s biggest melanoma rival (for now). This opens up the playing field for Amtagvi to dominate late-stage melanoma. Wall Street underestimated this shift. The author nails this. ✅ 2. Real-world response data is stunning 49% overall response rate in multi-failure patients is genuinely impressive. 60.9% in early-line patients? That’s rare territory — this could lead to earlier-line approvals, dramatically increasing patient pool. $500K/treatment with insurance coverage? That’s real monetization of innovation. ✅ 3. Management shakeup is meaningful Adding a real CCO and CFO with track records from successful biotechs adds confidence. The company has faced execution issues in the past — the team refresh is part of the solution. ✅ 4. Short interest + low float = potential squeeze 34.5% short interest with over 80% institutional ownership = only scraps left for retail to trade. If this gets momentum, there might not be enough shares to cover, which is the fuel for a proper short squeeze. --- 🧨 Weak Spots in the Thesis Let’s be honest — even solid DD has blind spots. Here are the main ones: Risk Reality Execution risk remains New team or not, commercial rollout in biotech is hard. Bottlenecks still possible. Lawsuit over prior disclosures There is an active securities lawsuit underway — could weigh on sentiment. Biotech volatility Even with good news, these names whip around like crazy. You could see –30% days for no reason. $1B revenue forecast is aspirational They need to prove they can hit even $200M/yr before markets buy into $1B talk. Still — none of these flaws invalidate the thesis. They’re just risks to factor in if you size up a position. --- 🎯 Price Targets: Are $10–15 realistic? Yes, but only with two key conditions: 1. Q2 earnings (likely in August) must confirm a ramp in sales and demand 2. No major delays or bad guidance from management If those two go well, the squeeze + fundamental re-rating could absolutely push this to $10–12 short-term, and possibly $15+ if uptake goes parabolic by year-end. --- 📦 Position Strategy (if you buy in) Entry Zone: ~$3.00–3.30 Stop-Loss: Optional, but a mental stop around $2.25–2.50 is fair Profit Target 1: $6–7 Profit Target 2: $10+ Add trigger: Above $4.00 on volume with Q2 guidance beat You can always scale in — start with a half-size and build into strength or news. --- 🏁 Final Word The Reddit post is smart, well-researched, and genuinely bullish for good reason. It’s not hype for the sake of it — it’s grounded in improving data, market dynamics, and a rare biotech setup. If you’re open to high-risk, high-reward biotech with real catalysts and a ridiculous squeeze setup, this is honestly one of the best asymmetric setups in the market right now. Let me know if you want a quick technical chart readout or to set trade alerts for breakouts or volume spikes.

Consistent_Log_3040

CCO

christed272

📊 AYTU – Superstock Checklist # Criterion Meets? Comments & Data 1 Price $1–$15 ✅ Yes $2.32 (July 16, 2025) 2 Breakout from strong base ✅ Yes Recent breakout after earnings, strong technical signals 3 Breakout above 30WMA ✅ Yes Price is well above 50- and 200-day MAs ($1.93 / $1.67) 4 Massive weekly volume ✅ Yes Typical: ~200k, recent spikes >1M (Finviz) 5 Steep angle of attack ✅ Yes Up 28% YTD, +34% after news; sharp move visible 6 Clean chart ✅ Yes Few gaps, clear uptrend since base 7 Prior momentum ✅ Yes Multi-month uptrend after strategic restructuring 8 Acts like a superstock (‘magic line’) ✅ Yes Outperforms other small-cap biotechs, clear breakout 9 EPS positive ✅ Yes Q3 FY25: $0.21; Q2 FY25: $0.13 10 Earnings sustainable ✅ Yes Revenue growth 2024–2025; recurring pharma income 11 P/E ≤ 10 ✅ Yes No standard P/E, forward P/S ~0.99; EV/EBITDA ~4 12 Sequential improvement ✅ Yes Q-on-Q improvement visible 13 Easy YoY comparison ✅ Yes +32% sales, +65% EBITDA YoY 14 High operating leverage ✅ Yes High margins, EBITDA >$600k on $18M sales (~22%) and growing 15 Increasing backlog ✅ Yes New contracts (EXXUA commercialization) show pipeline is growing 16 Insider buying? ✅ Yes CEO bought 15k shares @ $1.30; other officers also bought 17 Low float & market cap ✅ Yes ~$20M market cap, float ~6.7M shares 18 IT factor ✅ Yes Focus on ADHD/depression meds (EXXUA, Adzenys, etc.) 19 Conservative management ✅ Yes Strong cash, low debt/EBITDA ~2.9; refinancing April 2025 20 Simple headlines ✅ Yes “First-in-class antidepressant approved...” etc. 21 No listed options ❌ No Options available (Finviz) 22 Little/no competition ⚠️ Partial Biotech always has competition, but EXXUA is unique in its class 23 Low short interest (<20%) ✅ Yes Short interest very low (<5%) 24 Not highly leveraged ✅ Yes Debt/equity only 0.65 25 Not a commodity play ✅ Yes Pure pharma, no commodities exposure 26 IBD 100 ❌ No Not included 27 No analyst coverage ⚠️ Limited Lake Street covers it, but little mainstream coverage 28 Super traders on board ❌ No No large hedge funds or “supertrader” presence 29 Insider ownership 20–30% ✅ Yes Insiders/founders historically ~20%+ (CEO, CCO, etc.) 30 Long trading history, not recent IPO ✅ Yes Public since ~2015, no SPAC/recent IPO 31 Great ticker ✅ Yes “AYTU” is short, clear, and unique 📈 Score & Evaluation ✅ Fully met: 27 / 31 ⚠️ Partial: 22 (competition), 27 (analyst coverage), 16 (recent insider buys – present but not massive) ❌ Not met: 21 (options), 26 (IBD 100), 28 (supertraders) 🔍 Summary Aytu BioPharma is a very strong Superstock candidate per Jesse Stine’s method: ✔️ Profitable, breakout, high momentum ✔️ Low float, microcap, recurring revenue, strong new product (EXXUA) ✔️ Solid insider discipline, clear headlines, growing backlog ✔️ No commodity risk, low debt, minimal analyst/hype risk Risks: options exist, limited analyst coverage, biotech always has competition and event risk.

BlueChipGMC

CCO.TO I hope so at least

3xonblack

Buying BULL options is like donating to the CCO

LatentF

I personally like CCO, KAP (both nuclear). Also Veolia Environment, Lion Finance Group and Pfizer

LazyTitan39

He should have been a CCO instead of CEO.

bilingualbunny

Ill go in order of my largest holdings, CCO/CCJ, URA, EFR/UUUU, and DNN/DML

AlarmingAdvertising5

My only nuclear stock is Cameco CCO from Canada. Sell the uranium. 

BBpigeon

Thoughts on CCO? Does this baby still have room to run or is the nuclear party done?

bilingualbunny

CCO/CCJ let's gooooo!

Xalto-Tun

CCO.to for the win.

bilingualbunny

Absolutely, I'm in deep on UUUU, CCO, and URA Looking at DNN, any thoughts?

bilingualbunny

URA, CCO, UUUU, OKLO, LTBR, ASPI, DNN. ALL TO THE FUCKING MOON LETS GO 

Plastic-Injury8856

“We are China's largest trade partner at around $500B.” A number that hasn’t moved in a decade. China can easily secure more food elsewhere, sure at higher prices but most US exports are corn and sou, which directly contribute to obesity. The CCO will spin this as fighting obesity: We hold none of the cards. They don’t need us because we have nothing they need. We need their manufacturing. And with Trump putting tariffs on and off at a whim, no one is going to want to build factories here. Why build factories here if you can’t price your inputs reliably?

Wide-Cell6193

LOL you libbies are funny. I make an even keel cool 150 k a year as a certified CCO crane operator, I voted for Dems once. But Trump is a much better choice IMO. Dems have lost thier way dude. Enjoy your Kroger!

bilingualbunny

Any uranium plays with penny stocks? I'm mostly in URA, CCO, UUUU, and DNN. lost some money with PEGA on the tsxv. Thanks

jsmith108

Uranium should do well, but I have never been a big fan of DNN. Look at the long term chart. Far underperforms a stock like CCO.TO. Denison is poorly run and lives off of being a "cheap" listing for uranium bulls to support. Rather than actually developing a profitable and growing business with producing uranium assets. Management is there just to collect an easy paycheck IMO.

2nd_Tinder_Date

How much money under the table is the CCO funding deepseek is the real question? people really are dumb enough to believe data from Chinese companies

IronDefects

CCO, not a penny stock tho

Constant_Chemical_10

CCO. Dipping right now, but I'm holding long term.

Phoenixchess

QSI's making big moves in protein sequencing tech. Their [Platinum instrument was the first benchtop sequencer with single-molecule resolution](https://beyondspx.com/article/quantum-si-qsi-pioneering-the-future-of-protein-sequencing), and they just dropped a new library prep kit that cuts prep time to under 2 hours. Plus they [brought in Todd Bennett as CCO](https://beyondspx.com/article/quantum-si-qsi-pioneering-the-future-of-protein-sequencing) - dude's got 30 years in life sciences and is already expanding their sales channels. But blind trading is risky af. They're still burning cash while ramping up commercialization. Look into the tech and financials before yoloing. This isn't a meme stock - it's a legit biotech play that needs proper DD.

redditnosedive

u/ADropinInfinity I watched the middle east conference, CCO of Archer said there they struck a deal with Emirates leadership to have Archer fly their aircraft there in 2025, I think there is a chance it hits 9-10 today which is 200-300k for your pockets.

SnooPandas2519

There's 3 ways 1) Reverse split to let's say 1 to 4 wich would get them to 2 dollars 2) Make enough money to buy back stocks to drive up price 3) Just plug along and keep making money and hope investors are interested. 3 is the best option obviously. Now in my opinion, before the conference call the 11th I would not have known. It could go either way. Reverse splits suck. But after the 11th, they are in talks with a distributor for the VA. They also have the naval hospital in Guam. And they have a cardiac surgery fda approval pending along with a CE mark from the EU which would trigger a distributor to make a lump sum prepayment. The forecast is in December. My advice would be to go to the investor relations section of Beyond Air Inc's website and sign up for updates. They send their press releases, sec filing and so on. As far as I can tell from the shareholders meeting, a Reverse split is not on the table as of yet. They also got some big name investors to go in. I can't tell you to get in or not. But for me, I'm not worried about it delisting. Not to plug my channel. But I do have a YouTube channel devoted to my investment and there you can hear earnings calls and other news. I try to be as unbiased as possible. (Of course harder said then done) the name is xairinvestor. I recently posted the earnings call from the 11th. My biggest thing is their CEO and CCO are both experienced in being in such a precarious position and pulling off a win. It definitely is a razors edge. Mid February is the delisting deadline.

DragonNinja420

took my 4000% MSTR gain, maxed out my First Home Savings Account and put the rest back into MSTR calls. Got shares of CCO (cameco) & PRL (propel holdings)

throw60659

CCO. 28% of the world's raw uranium.

scithe

NLR holds SMR, CCO (U.S. CCJ) and OKLO so not a bad choice.

Actiontodayo7

In a volatile market like uranium, I prefer to go for established companies with a greater moat and dominance. This will reduce risk although the premiums on eps is higher. For example: Cameco (CA:CCO/ US:CCJ) is a solid leader in the uranium world, thanks to its large, high-quality reserves and its integrated setup that covers everything from mining to fuel production. One of its big advantages is locking in long-term contracts, usually around 5-10 years, which keeps cash flow steady and shields it from the ups and downs in uranium prices. This is a common practice for major players, though even smaller producers go for similar deals to keep things stable. They uranium to 37 nuclear utilities worldwide, with 58% of its volume delivered to the Americas, 16% to Asia, and 26% to Europe. The company’s five largest customers account for 62% of its commitments.  Globally, the United States, China, and France are the leading consumers of uranium, collectively representing approximately 58% of the global demand.  With YoY demand increasing, I suspect uranium is bullish in the long run as more reactors (both traditional and modular) are going online next the next 5-10 years.

i_eat_babies__

> ROIC is misleading when you work with early stage tech development because once you DO manage to commercialize the tech profitably then ROIC normalizes. This is a really interesting perspective. I think I've become too hyper-fixated on the bean-counting aspect of things (ROIC, P/E, EPS), which doesn't necessarily apply for developing companies. Also 200% agreed with the Tesla perspective. Are there any Uranium ETF's you've been looking at? I quickly glanced at URA (Global X Uranium ETF) and NLR (Van Eck's ETF); I like the companies in URA more, but the balance is so off. 24% of the ETF being one stock (CCO: Cameco Energy) is a bit too much to me.

ssferland

CCO = Clear Channel Outdoor Holdings

Neither-Macaroon5723

ARTG CCO PNG and E is why...

Neither-Macaroon5723

Canadian companies like ARTG TEC CCO PNG and BDT or... just buy a S&P index ETF and make 20-30% a year but like... I'd prefer 100+% of my money a year not 30%

Neither-Macaroon5723

What the reply error said but don't dollar cost average just on these specific stocks/etfs. They do a good 25-30% all year long not matter when you check ytd. So 30% per year after 10 years that 300% your investment and its the safest play you can make getting into the market. Personally I I vest in Canada and buy ARTG TEC E PNG and CCO at the moment thats... into the thousands of percentage gains in 10 years.

Zorkonio

Was looking at CCO today on tsx. Canadian uranium company and their PE is 130 Rn. Spiked big time from this news

Queasy_Ad_4705

Positions. 70k@CAD 57 CCO

New_Possible_284

Borrow yuan, buy Chinese stocks, CCO print money, Chinese stocks go up, you return your loan, and make a lot of money. Question: how do you borrow yuan

SeniorVicePrez

Cameco trades as CCO (TSX) in Canada